^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Estybon (rigosertib)

    i
    Company:
    Knight Therap, Pint Pharma, Specialised Therap, SymBio Pharma, Traws Pharma
    Drug class:
    PI3K inhibitor, PLK1 inhibitor, RAS antagonist
    Related drugs:
    Apply
    Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors (NCT05764395)
    Phase 2
    Vanderbilt-Ingram Cancer Center
    Recruiting
    Last update posted :
    06/10/2024
    Initiation :
    05/09/2023
    Primary completion :
    05/01/2028
    Completion :
    05/01/2029
    BRAF
    |
    BRAF mutation • BRAF V600
    |
    Keytruda (pembrolizumab) • Estybon (rigosertib)
    Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment (NCT04263090)
    Phase 1/2
    Icahn School of Medicine at Mount Sinai
    Completed
    Last update posted :
    05/09/2024
    Initiation :
    06/29/2020
    Primary completion :
    12/20/2023
    Completion :
    12/20/2023
    KRAS
    |
    KRAS mutation
    |
    Opdivo (nivolumab) • Estybon (rigosertib)
    Safety Study of ON 01910.Na in Combination With Irinotecan or Oxaliplatin (NCT00861328)
    Phase 1
    Onconova Therapeutics, Inc.
    Completed
    Last update posted :
    06/23/2017
    Initiation :
    02/01/2008
    Primary completion :
    07/01/2011
    Completion :
    07/01/2011
    UGT1A1
    |
    UGT1A1*1*1
    |
    oxaliplatin • irinotecan • Estybon (rigosertib)